2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Bioinformatics, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Immune Mechanism, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, ALL, B Cell Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

3308 Genomically directed tucidinostat or dasatinib combined with chemotherapy for adult Philadelphia Chromosome–like acute lymphoblastic leukemia: Long-term results of a Phase 2 study

Xiuli Xu, Jiaxin Zheng2, Wenhao Zhong3, Zhixiang Wang4, Xuan Zhou, PhD5, Bailin He6, Li Xuan7, Qifa Liu, MD8, Hongsheng Zhou9
1 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
2 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
3 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
4 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
5 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
6 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
7 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
8 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
9 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Background: Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL) is a high-risk subtype characterized by diverse kinase-activating alterations and poor outcomes with conventional chemotherapy. We evaluated a genomically directed treatment strategy using tucidinostat or dasatinib combined with chemotherapy in adolescents and adults with newly diagnosed Ph-like ALL.

Methods: This open-label, multicenter, nonrandomized phase 2 study enrolled patients aged 14–55 years with newly diagnosed Ph-like ALL. Patients were assigned to two treatment cohorts according to their molecular alterations. Patients with JAK–STAT pathway alterations, including CRLF2, EPOR, or JAK2 rearrangements and other predefined pathway mutations, received tucidinostat at 10 mg orally once daily. Patients with ABL-class alterations, including ABL1, ABL2, CSF1R, or PDGFRB rearrangements, received dasatinib at 100 mg orally once daily. Both targeted agents were administered with pediatric-inspired, measurable residual disease (MRD)-directed chemotherapy from induction through consolidation. The primary endpoint was 3-year event-free survival (EFS). Secondary endpoints included composite complete remission (CR/CRi), end-of-induction MRD negativity, overall survival (OS), and safety. MRD negativity was defined as an MRD level <0.001 by multiparameter flow cytometry.

Results: A total of 48 patients were enrolled, including 30 in the tucidinostat cohort and 18 in the dasatinib cohort. The median age was 26 years (range, 14–55). Overall, 34 patients (70.8%) achieved CR/CRi after the first induction, and 28 (58.3%) achieved MRD negativity. The CR/CRi rates were 70.0% and 72.2%, and the MRD-negative rates were 53.3% and 66.7%, in the tucidinostat and dasatinib cohorts, respectively. Twenty-seven patients (56.3%) underwent allogeneic hematopoietic stem cell transplantation.

After a median follow-up of 45.7 months, the estimated 3-year EFS and OS rates for the overall cohort were 55.8% (95% CI, 40.6–68.6) and 74.6% (95% CI, 59.6–84.7), respectively. In the tucidinostat cohort, the 3-year EFS and OS rates were 49.5% (95% CI, 30.7–65.8) and 69.7% (95% CI, 49.7–82.9), respectively. In the dasatinib cohort, the corresponding rates were 66.7% (95% CI, 40.4–83.4) and 83.3% (95% CI, 56.8–94.3), respectively.

Conclusions: Genomically directed addition of tucidinostat or dasatinib to chemotherapy produced encouraging responses and long-term survival in patients with Ph-like ALL harboring JAK–STAT or ABL-class alterations. These findings support molecularly stratified targeted therapy as a feasible treatment strategy for Ph-like ALL. (ClinicalTrials: NCT03564470.)

Xiuli Xu: No relevant conflicts of interest to declare.